Umbilical cord blood (UCB) is an attractive stem cell graft option for patients who need allogeneic hematopoietic stem cell support, but lack a suitable HLA-matched donor. However, the limited number of hematopoietic progenitor cells in a single cord blood unit can lead to an increased risk of graft failure, delayed hematological recovery and prolonged immunosuppression, particularly in adult patients. Several strategies to overcome these potential limitations are being evaluated. In this review, we discuss promising ex vivo manipulations to enhance cord blood engraftment capacity such as culture of UCB cells with stimulatory cytokines and growth factors, mesenchymal cells, Notch ligand, copper chelators, prostaglandins, complement components, nicotinamide and CD26/DPPIV inhibitors. All these approaches are now in early clinical trials. However, despite the fact that several cord blood enhancement strategies have resulted in increased numbers of progenitor cells and faster neutrophil recovery, the ability of these techniques to significantly shorten engraftment time and permit the use of cord units with low numbers of total nucleated cells, or accomplish reliable engraftment with a single cord, have yet to be convincingly demonstrated. The ultimate clinical value of ex vivo cord blood expansion or manipulation has not been defined yet, and the current data do not permit predicting which technology will prove to be the optimal strategy. Nevertheless, expectations remain high that eventually ex vivo enhancement will be able to improve clinical outcomes and significantly extend the applicability of UCB transplantation.
INTRODUCTION
Use of umbilical cord blood (UCB) for hematopoietic support has been steadily increasing worldwide. 1 Ease of collection, prompt availability of cryopreserved units, reduced incidence and severity of GVHD, and the ability to tolerate HLA disparity with the recipient due to the immunological naiveté of the cord blood immune progenitors make UCB an attractive option for patients lacking a suitable HLA-matched donor. However, the limited number of hematopoietic progenitor cells (HPC) in a single UCB unit often is associated with slow hematopoietic recovery, prolonged immune reconstitution and high risk of graft failure, particularly in adult patients. To compensate, commonly, infusion of two unrelated UCB units also known as 'double UCB transplantation (dUCBT)' is utilized; however, early post-transplant complications remain unacceptably high. 2 Several other strategies, such as optimization of myeloablative conditioning, 3 increasing HPC yield at collection 4 and minimization of HPC loss during processing and thaw, can also lead to improved rates of engraftment and faster neutrophil recovery. However, ex vivo UCB enhancement may offer even greater promise of significantly abrogating post transplant engraftment and facilitating immune reconstitution. Despite the ability of several UCB enhancement techniques to significantly increase the number of HPC in a single UCB unit in preclinical studies, only few of them have been the subject of vigorous clinical research (Table 1) . This article will review promising UCB enhancement technologies, which are currently being evaluated in clinical studies to enhance UCB graft potency and use in UCB transplantation (UCBT).
EX VIVO MANIPULATIONS TO ENHANCE UCB GRAFT POTENCY: PRECLINICAL AND CLINICAL APPROACHES
The most advanced ex vivo UCB enhancement strategies include the following: (1) culture in the presence of stimulatory cytokines and hematopoietic growth factors; (2) Notch ligand-mediated expansion; (3) culture with mesenchymal stem cells; and (4) culture in the presence of various agents, such as copper chelators, prostaglandins, complement components, nicotinamide or CD26/DPPIV (CD26/dipeptidyl peptidase IV) inhibitors. These strategies are discussed in detail below.
Culture in the presence of stimulatory cytokines and growth factors A number of studies over two decades have established that hematopoietic progenitors derived from BM, peripheral blood and UCB can be successfully expanded by co-culture in the presence of stimulatory cytokines and hematopoietic growth factors, and used in clinical hematopoietic SCT. 5, 6 The types of growth factors have varied from study to study, but most contain SCF, Flt-3 ligand, and TPO, among others, such as GM-CSF, IL6 and IL3. The majority of these studies have demonstrated expansion of total numbers of cells, mostly more differentiated progenitors, without clear demonstration of increased numbers of undifferentiated stem cells. The methodologies have differed, and today it remains unclear what methodology is best; what is the best mix of growth factors, the optimal concentrations of these reagents, whether a preparation of selected immature cells (and which cell population) 1 Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA and are better for expansion than unselected cells, whether a bioreactor is better than static liquid cultures, whether liquid cultures alone are sufficient without cell-to-cell contact, nagging concerns about long-term engraftment, and whether the ex vivo manipulation introduces defects in apoptosis, homing, or other functions necessary for engraftment and immune reconstitution. Most important, none of the technologies studied to date have offered conclusive demonstration of substantially improved shortterm and long-term engraftment, or improved immune reconstitution. 5, 6 The technological challenges that remain make this technological platform unlikely to reach clinical application in the near future.
Co-cultivation with mesenchymal stem cells Cell-to-cell contact is believed to be an important facet of stem cell growth in addition to the presence of soluble growth factors. Being an essential component of the hematopoietic microenvironment, MSCs have been shown to facilitate self renewal and differentiation of HPC. 7 Co-culture of UCB units with MSCs and stimulatory cytokines (G-CSF, SCF and TPO) has been shown to promote superior total nucleated cells and HPC expansion in comparison with UCB expansion in liquid cultures containing the same cocktail of cytokines. 8 A phase 1 clinical trial demonstrated safety and feasibility of UCB expansion in the presence of third-party MSCs and cytokines. In that study, MSCs were obtained from either a haploidentical family member or from unrelated mesenchymal progenitor cells produced using commercially available in vitro technology. All patients received myeloablative conditioning followed by dUCBT with one of the two UCB units being expanded in the presence of MSCs. The presence of MSCs facilitated a median 40-fold expansion of HPC without any apparent safety concerns or increased GVHD risk. The median time to neutrophil and platelet recovery was 15-40 days, respectively, which appeared to be shorter than a historical control group. Long-term engraftment at 6 months post transplant was provided by the unmanipulated unit, 9 suggesting that the role of the manipulated UCB unit was to facilitate engraftment of the other cord. Questions as to long-term engraftment effects of this manipulation remain. This technology is expected to enter a phase 3 trial during this calendar year. 
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Notch-mediated expansion Insights into the molecular mechanisms that govern stem cell maintenance, self-renewal and differentiation are growing. Manipulation of the signaling pathways that underlie these phenomena hold great promise in overcoming the challenges of cord blood expansion. The Notch signaling pathway has an important regulatory role in the expansion and differentiation of human HPC. 10 Preclinical data have shown the ability of engineered Notch ligands to influence HPC differentiation. Incubation of murine marrow precursors in the presence of Notch ligand and stimulatory cytokines, such as SCF, IL-6, IL-11, Flt3-l, IL-7 and GM-CSF, resulted in a several-log increase in the number of hematopoietic precursors, which were capable of differentiating into mature lymphoid and myeloid cells. 11 Delaney et al. 12 conducted a phase 1 trial, investigating the feasibility and safety of Notch-mediated UCB expansion. In that study, a single T-cell depleted UCB unit was expanded ex vivo in presence of immobilized Notch ligand and infused into 10 patients with acute leukemia given a myeloablative conditioning regimen 4 h after infusion of an unmanipulated single UCB unit. T-cells removed from the expanded unit at the time of CD34 þ cell enrichment were not re-infused (no T-cell addback) because of concerns that the expanded UCB precursors would be negatively affected by T cells contained in the unmanipulated unit. This procedure was safe, did not increase the incidence of GVHD and led to significantly faster neutrophil engraftment at a median of 16 days as compared with 26 days in a matched dUCBT cohort. There were no engraftment failures. In half of the patients, myeloid engraftment occurred from the unmanipulated graft, which raised the possibility that the Notch-expanded UCB unit facilitated engraftment of the unmanipulated stem cells. A phase 2 trial is planned for the near future. Although manipulation of the pathways regulating hematopoiesis is promising, the status of this technology has not been explored sufficiently to know its ultimate promise. Further, multiple other regulatory pathways of hematopoiesis may also be exploitable for expansion and are being studied in preclinical investigations, 5 although these are further behind in the movement to clinical trials.
Copper chelation Certain agents may indirectly affect the pathways regulating hematopoiesis. It is known that copper deficiency is frequently associated with pancytopenia due to 'maturation arrest' of hematopoietic progenitors. This clinical observation stimulated research into the regulatory role of cellular copper in the proliferation and differentiation of HPC. Cellular copper reduction in the presence of the copper chelator tetraethylenepentamine (TEPA) results in delays in progenitor differentiation and promotes expansion of cord blood-derived CD34 þ cells in cytokinesupplemented liquid medium. 13 Exposure of UCB progenitors to TEPA in cultures containing stimulatory cytokines (SCF, TPO, IL-6 and FLT-3 ligand) produced an 89-fold increase in CD34 þ cells, 14 which provided a scientific basis for a phase 1-2 clinical trial to test the feasibility and safety of TEPA-mediated HPC expansion. 15 In that study, a single UCB unit was divided, with one aliquot cultured in cytokine-enriched media containing TEPA for 21 days, which resulted in a 219-and 6-fold expansion of total nucleated cells and CD34 þ cells, respectively. Then expanded UCB progenitors were administered 24 h after infusion of the unmanipulated fraction of the same UCB unit to 10 patients who received myeloablative conditioning for various hematological malignances. Despite the infusion of a relatively low number of total nucleated cells per kilogram (median of 1.8 Â 10E7/kg), nine patients engrafted at a median time to neutrophil and platelet engraftment 30-48 days, respectively. There was no increase in non-relapse mortality or the rate of acute GVHD in comparison with historical controls. This strategy proved to be feasible and demonstrated that TEPA-expanded UCB graft with low total nucleated cell numbers can be safely used with a hematopoietic recovery time similar to that observed in unmanipulated sUCBT. A much larger phase 2 trial is underway and will be completed in the near future.
Dimethyl-prostaglandin E2-mediated enhancement of HPC Prostaglandins promote an increase in number of HPC; however, the exact mechanisms of their actions remain to be elucidated. Prostaglandins enhance both HPC self-renewal and HPC repopulation in the BM by controlling the Wnt signaling cascade, 16 by a direct effect on the BM microenvironment, 17 by inhibiting apoptosis through an upregulation of survivin and a reduction in intracellular caspase-3, 18 and by enhancement of homing via upregulation of surface expression of CXCR4. 18 Preclinical data demonstrated that dimethyl-prostaglandin E2 significantly increases human hematopoietic colony formation in vitro and enhances engraftment of CD34 þ cord blood cells after xenotransplantation. 19 In a phase 1 clinical trial, 12 patients received reduced-intensity conditioning followed by dUCBT, where one of the two infused UCB units underwent expansion in the presence of dimethyl-prostaglandin E2 and the second unit was infused unmanipulated. This study demonstrated the feasibility and safety of this approach. Median time to neutrophil engraftment was 17.5 days as compared with 21 days in historical controls, with no instances of primary or secondary graft failure, and similar rates of severe acute and chronic GVHD. The expanded unit dominated in 9 out of 11 evaluable patients. 20 Priming with C3a complement component Preclinical data showed the ability of complement component C3a to enhance homing and engraftment of HPC. 21 A phase I study demonstrated that co-infusion of a C3a-primed and an unprimed UCB unit to patients with hematological malignancies after a myeloablative conditioning was safe and feasible. Priming with C3a was very simple and performed by incubation of a UCB unit with commercially available human C3a complement component for 30 min. Then, the C3a-primed unit was infused without washing 30 min after infusion of the unmanipulated cord. Neutrophil engraftment occurred at a median of 7 days as compared with 12 days in matched historical controls, and in two thirds of patients, engraftment was by the manipulated cord. 22 Although promising, further data are needed to fully assess the prospects of this approach.
Nicotinamide (NAM)-mediated expansion NAM is a form of vitamin B3 (niacin), which in addition to being a potent inhibitor of several ribosylase enzymes requiring NAD þ for their activity, also inhibits the sirtuin family of histone and protein deacetylases. 23 NAM delays differentiation and enhances migration, homing and engraftment of CD34 þ cells by inhibiting SIRT1 deacetylase. NAM-mediated enhancement of engraftment efficacy results from delayed differentiation of UCB progenitors, which favors their self renewal. 24 In a small pilot phase I study, seven patients with high-risk hematological malignances received myeloablative conditioning followed by dUCBT, where one of two cord units was expanded in the presence of NAM (NiCord technology). NAM-mediated expansion resulted to a median 82-fold increase in the CD34 þ cell dose. Neutrophil engraftment was robust at a median time of 10 days (range [7] [8] [9] [10] [11] [12] [13] [14] and durable with no increased toxicity. There were no graft failures and long-term engraftment was obtained from the expanded unit (authors' personal communications). The study is still ongoing and more patients are needed to form conclusions regarding the feasibility and safety of this approach.
Homing enhancement by CD26/DPPIV inhibitors Preclinical studies have demonstrated that inhibition of CD26 peptidase activity enhances homing, engraftment and competitive repopulation of hematopoietic progenitors. 25, 26 These observations established a basis for the clinical use of CD26 inhibitors to enhance UCB grafts. A phase II trial utilizing a CD26/ DPPIV inhibitor Sitagliptin to enhance engraftment after UCBT in adult patients with hematological malignancies is currently ongoing at Indiana University.
ANALYSIS OF CURRENT APPROACHES
Ex vivo enhancement of UCB is a promising strategy to overcome the obstacles associated with low progenitor cell yield in single cord units, improve clinical outcomes and expand the indications for UCBT. One of the hopes for UCB enhancement strategies is to generate a sufficient number of HPC to successfully perform sUCBT. However, despite two decades of studies, no technology has become approved or adopted into clinical practice.
Ideally, UCB graft enhancement strategies should achieve all of the following: (1) generate a sufficient quantity of HPC to eliminate the need for a second UCB unit; (2) improve clinical outcomes by shortening of time to hematopoietic engraftment, facilitating immune reconstitution and reducing the incidence of graft failure; (3) provide durable engraftment of expanded stem cells; (4) be safe and not increase the incidence and severity GVHD; (5) be easily adoptable by various transplant centers; and (6) be cost effective. Unfortunately, none of currently available UCB enhancement approaches fulfill all of these requirements. Table 1 illustrates the comparative advantages and disadvantages of the approaches described above to enhance graft potency and hematopoietic recovery in the course of UCB transplantation.
Various expansion technologies have shown significant increases in the number of cord blood progenitors, and several have shown some improvement in clinical engraftment in clinical trials. In the majority of UCB enhancement strategies currently in clinical trials, infusion of a second unmanipulated UCB unit was still needed to ensure long-term engraftment (Table 2 ). Substantial benefits due to faster hematopoietic recovery and more robust immune reconstitution need to be shown to justify the added cost of the expansion technology and the cost of a second unit. As yet, none of the technologies have shown improved immune reconstitution. Interestingly, for several of the expansion approaches, it appears that the unmanipulated cord is the cord that is responsible for long-term engraftment. Thus, the role of the manipulation appears to facilitate of early engraftment and nurturance shortly after UCBT. The need for extensive processing and expertise should be considered as another significant shortcoming of many UCB expansion approaches, which would potentially limit their widespread utilization by multiple transplant centers. In this regard, techniques that require minimal processing, such as PGE2-or C3a-medited expansion, if proven to be effective in large clinical trials, will have significant practical advantage. As yet, the paucity of published clinical trial data makes prediction of which technology is most suitable impossible.
OBSTACLES TO CLINICAL DEVELOPMENT
One of the challenges facing development of new cord blood manipulation technologies is the sizable number of technologies competing for a limited pool of patients undergoing UCBT, and the numbers of patients undergoing dUCBT (presumably the major target population for such studies) is even smaller. As of 2010, fewer than 20 centers in the United States performed more than five UCB transplants per year in patients 6 years of age or older as reported to the CIBMTR (Horowitz MM, personal communication). In total, only approximately 250 UCB transplants were being performed annually in individuals over the age of 16, the group in which these studies are best suited. If all technologies cannot be tested at once, prioritization will be quite difficult from a scientific perspective from what is currently known.
Moreover, study design issues, such as choice of the optimal conditioning regimen, ablative vs reduced-intensity conditioning, type of GVHD prophylaxis, single vs double UCB used as the graft, disease and age range, must all be addressed to allow comparisons between studies and allow comparisons with historical data. Finally, there is debate as to the most suitable primary endpoint: should it be a short-term outcome such as engraftment, or should it be a long-term outcome such as survival at 1 year?
FUTURE CONSIDERATIONS
In Table 3 , we have summarized ongoing or planned phase II/III studies utilizing ex vivo UCB expansion. The ultimate clinical value UCB expansion strategies have not been finally defined yet. Future development of successful UCB enhancement approaches should solve number of existing controversies (Table 4) . First, does one need to select a subset of cells to expand, and if so, which cell subpopulation to expand must be defined. Second, the most optimal conditions for UCB ex vivo expansion need to be determined, whether or not liquid cultures, static or continuous perfusion cultures with or without stromal cells must be defined. Third, manipulation of the molecular pathways that regulate stem cell maintenance and self-renewal appears most promising, but this is still in its infancy of development. Fourth, better ways to increase cell yield at the time of collection, and reducing cell loss during processing and at time of thaw are important lines of inquiry. Fifth, methods to enhance homing are also promising but still need testing in clinical trials. Sixth, the long-term fate of expanded UCB progenitors also remains unclear and it is not known if certain manipulations may be associated with earlier senescence or apoptosis. 
